{"id":"W4405045423","doi":"10.1182/blood-2024-194827","title":"Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Phases of clinical research; Tolerability; Leukemia; Oncology; Refractory (planetary science); Acute leukemia; Gastroenterology; Adverse effect; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001906902,0.002007437,0.001827359,0.0004023003,0.0004525339,0.001141015,0.001015286,0.001346847,0.007346181],"category_scores_gemma":[0.0009148106,0.0005893178,0.001118983,0.000379788,0.0006481725,0.0008068751,0.000343185,0.002957311,0.001486289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001015984,"about_ca_system_score_gemma":0.001861282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009501319,"about_ca_topic_score_gemma":0.003370592,"domain_scores_codex":[0.9995208,0.0002368501,0.0000242596,0.00007562672,0.00005231006,0.00009016492],"domain_scores_gemma":[0.9994956,0.00006420986,0.0001055445,0.00004632782,0.0000606198,0.0002275751],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5939322,0.08108081,0.01137288,0.003136402,0.002978858,0.0008427019,0.0004307097,0.004793841,0.09539467,0.0007886491,0.03451446,0.1707338],"study_design_scores_gemma":[0.5954412,0.3581495,0.01620281,0.0001267043,0.0008288926,0.0008990742,0.00006599511,0.001364506,0.01020528,0.0005152192,0.01614625,0.00005452778],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9387823,0.01045153,0.003376542,0.002393633,0.0003666462,0.01863224,0.01659315,0.0006613335,0.008742604],"genre_scores_gemma":[0.929336,0.007663709,0.009012681,0.004358381,0.0004422612,0.01444383,0.01835707,0.0001956615,0.01619057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007346181,"threshold_uncertainty_score":0.02457541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008586955842984497,"score_gpt":0.2690134804382673,"score_spread":0.2604265245952828,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}